2026-04-03 06:19:35
Cabergoline is a highly selective long-acting dopamine D2 receptor agonist, the first-line treatment for hyperprolactinemia (HPRL), pituitary prolactinoma, and physiological lactation suppression. Its core clinical dosing strategy follows low-dose initiation with gradual individualized titration. This article details its full clinical specifications, including dosing regimens, dose adjustment principles, indication-specific treatment duration, and post-discontinuation monitoring.
2025-10-19 11:44:20